| dc.contributor.author | Abassi, Mahsa | |
| dc.contributor.author | Rhein, Joshua | |
| dc.contributor.author | Meya, David B. | |
| dc.contributor.author | Boulware, David R. | |
| dc.date.accessioned | 2025-05-13T09:51:51Z | |
| dc.date.available | 2025-05-13T09:51:51Z | |
| dc.date.issued | 2017 | |
| dc.identifier.citation | Abassi, M. et al. (2017). Cryptococcal disease in the era of “test and treat”: Is there cause for concern? Open Forum Infectious Diseases, 5(1) 1- 4. | en_US |
| dc.identifier.uri | https://doi.org/10.1093/ofid/ofx274 | |
| dc.identifier.uri | http://hdl.handle.net/10570/14525 | |
| dc.description.abstract | Treatment of cryptococcosis requires deferred initiation of antiretroviral therapy (ART). Early ART initiation may be detrimental in the context of cryptococcal infection by increasing the risk of immune reconstitution inflammatory syndrome (IRIS). We present 3 cases where early ART initiation in the presence of unrecognized cryptococcal disease had fatal outcomes. | en_US |
| dc.description.sponsorship | The Fogarty International Center,
The National Institute of Neurological Disorders and Stroke,
The National Institute of Allergy and Infectious Diseases of the National Institute of Health,
DELTAS Africa Initiative. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Oxford University Press | en_US |
| dc.subject | Cryptococcosis treatment | en_US |
| dc.subject | Immune reconstitution inflammatory syndrome | en_US |
| dc.subject | Antiretroviral therapy | en_US |
| dc.subject | ART | en_US |
| dc.subject | HIV/AIDS | en_US |
| dc.subject | CD4 cell count | en_US |
| dc.title | Cryptococcal disease in the era of “test and treat”: Is there cause for concern? | en_US |
| dc.type | Article | en_US |
